Bank of America Securities has reiterated its Buy rating on Nvidia (NVDA) stock with a price target of $200. This price target represents an upside of 66%
To Read This Paid Research For Free Subscribe Now: AlphaBinwaniCapital.com
Bullion climbed above $3,039 an ounce, beating the previous all-time high set in the previous session. Russian President Vladimir Putin refused to give Donald Trump the 30-day ceasefire in Ukraine he and his team had demanded on the path toward ending the three-year conflict. Safe haven demand has also risen this week as Israel ended its Hamas ceasefire with airstrikes across Gaza, killing hundreds
Discover how we can elevate your portfolio and deliver exceptional growth. NEW Monthly Payout Of At Least 0.5% In US Dollars
Bank of America and Needham have both named Salesforce as a top stock pick for 2025. The consensus price target from analysts is around $401, suggesting nearly 30% upside potential from recent trading levels
To Read This Paid Research For Free Subscribe Now: AlphaBinwaniCapital.com
China’s stock rally may face a “meaningful correction soon” given its similarities with the 2015 boom and bust cycle, according to strategists at BofA securities
To Read This Paid Research For Free Subscribe Now: AlphaBinwaniCapital.com
Donald Trump’s White House is rumored to be considering large-scale bitcoin purchases, while crypto trader Arthur Hayes predicts Federal Reserve intervention to stabilize markets. Hayes suggests this could potentially lead to a significant increase in bitcoin prices
To Read This Paid Research For Free Subscribe Now: AlphaBinwaniCapital.com
Nvidia’s new Blackwell Ultra chip delivers 1.5 times more AI performance than its predecessor, the NVIDIA GB200 NVL72. It provides up to 15 petaFLOPS of dense 4-bit floating-point performance, which is a 50% increase over the previous generation
To Read This Paid Research For Free Subscribe Now: AlphaBinwaniCapital.com
Exclusive Insights. Decisive Advantage Our Newsletter: Your Gateway to Privileged Intelligence
Don’t just follow the crowd. Lead it Our newsletter delivers:
✓ Paid research inaccessible to the general public ✓ Critical insights for high-stakes decision-making ✓ Cutting-edge analysis that puts you ahead of the curve
While others guess, you’ll know
Join for FREE today and transform your decision-making process with intelligence that matters
Novo Nordisk has announced it will present new data on semaglutide’s ability to lower heart risks at the upcoming American College of Cardiology Scientific Session and Expo. This news has sparked investor interest in the potential expanded applications of Novo’s key drug ingredient
Discover how we can elevate your portfolio and deliver exceptional growth. NEW Monthly Payout Of At Least 0.5% In US Dollars
AlgoTrader 